Skip to main content
. Author manuscript; available in PMC: 2021 Feb 7.
Published in final edited form as: Leukemia. 2020 May 7;35(2):377–388. doi: 10.1038/s41375-020-0845-6

Figure 3. SHIN2 has an antileukemic effect in T-ALL in vivo.

Figure 3.

(a-b) Representative images from treated mice (a) and quantification (b) of changes in tumor burden at day 3 and day 5 post-treatment initiation with (+)SHIN2 (200 mg/kg, BID) as assessed by bioimaging in mice allografted with NOTCH1-induced mouse leukemia cells (n=9 for vehicle; n=10 for (+)SHIN2). P values were calculated using a two-tailed unpaired Student’s t-test. (c) Changes in leukemic burden at day 4 post treatment initiation with (+)SHIN2 (200 mg/kg, BID) as assessed by FACS detection of leukemic GFP-positive cells in peripheral blood (n=9 for vehicle; n=10 for (+)SHIN2). P value was calculated using a two-tailed unpaired Student’s t-test. (d) Kaplan-Meier survival curves of mice harboring NOTCH1-induced mouse T-ALL treated with vehicle or (+)SHIN2 (200 mg/kg) for 11 days (log-rank test; **P<0.01) (n=9 for vehicle; n=10 for (+)SHIN2).